Joachim Wink

This inventor holds 31 USPTO granted patents and 3 published patent applications and 8 EPO patents, primarily in Antibiotic Development. Top assignees: Hoechst Aktiengesellschaft, Aventis Pharma Deutschland, Gmbh, Sanofi. Active years: 1990-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Joachim Wink. Retrieved from https://idiyas.com/inventor/joachim-wink

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 31 (Patent Applications = 3)

% Patents Active = 80.6

EPO Patents = 8 (Patent Applications = 5)

Average Co-Inventor Count = 5.5

ph-index = 5

Forward Citations = 95(Granted Patents)

Location History:

Offenbach, DE (1990 - 1996)
Rodermark, DE (1993 - 2006)
Rödermark, DE (2001 - 2007)
Frankfurt-am-Main, DE (2011 - 2016)

Company Filing History:

17 out of 6,705

Hoechst Aktiengesellschaft

patents

7 out of 330

Aventis Pharma Deutschland, Gmbh

Sanofi-A Ventis Deutschland Gmbh

patents

5. 1 out of 18

Hoechst Marion Roussel Deutschland Gmbh

Years Active: 1990-2016

Loading Chart...

Areas of Expertise:

Antibiotics

Antifungal Peptides

Lipopeptides

Griselimycin

Cyclipostins

Citrullimycines

Polyenes

Streptomyces

Furans

Lactones

Neurological Treatments

Immunosuppression

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9422566 - Gene cluster for biosynthesis of griselimycin and methylgriselimycin (2016-08-23),

2. 8765799 - Streptospirole derivatives (2014-07-01),

3. 8476222 - [object Object] (2013-07-02),

4. 7923438 - Use of cyclipostin derivatives for the treatment of mycobacterial infectious diseases (2011-04-12),

5. 7259276 - Polyenecarboxylic acid derivatives, processes for preparing them, and their use (2007-08-21),

6. 7041649 - Method for treating neurological conditions and inducing immunosuppression with cephaibols (2006-05-09),

7. 6930130 - Citrullimycines, a process for their production and their use as pharmaceuticals (2005-08-16),

8. 6756402 - Cyclipostins, process for their preparation and use thereof (2004-06-29),

9. 6500936 - Pluraflavins and derivatives thereof, process for their preparation and use thereof (2002-12-31),

10. 6472158 - Ustilipides, method for the production and the use thereof (2002-10-29),

11. 6387943 - Vancoresmycin, a process for its production and its use as a pharmaceutical (2002-05-14),

12. 6337411 - Stromelysin inhibitors (2002-01-08),

13. 6221844 - Antifungal peptides from scleroderma texense (2001-04-24),

14. 6194383 - Lipopeptides from actinoplanes sp. with pharmacological action, process for their production and the use thereof (2001-02-27),

15. 6022851 - Lantibiotic related to actagardine, and processes for the preparation (2000-02-08),

Title: The Innovative Contributions of Joachim Wink

Introduction: Joachim Wink, based in Rödermark, Germany, is a distinguished inventor with an impressive portfolio of 31 patents. His work primarily focuses on the biosynthesis of antibiotic agents and compounds with significant pharmaceutical applications. Wink's contributions to the field of biotechnology have made him a prominent figure in developing innovative solutions against bacterial infections.

Latest Patents: Among Joachim Wink's notable recent inventions is the patent for a gene cluster involved in the biosynthesis of griselimycin and methylgriselimycin. This invention encompasses the gene cluster and the genes contained within, which are essential for producing these antibiotic agents. The implications of this invention are vast, as it presents new opportunities for antibiotic production through biotechnological advancements. Additionally, Wink holds a patent for streptospirole derivatives, where he details a process to prepare these compounds by fermenting a particular strain of microorganism (sp. ST 108140) and utilizing these for the development of medicaments aimed at treating and preventing bacterial infections.

Career Highlights: Throughout his career, Joachim Wink has worked with prominent companies such as Hoechst Aktiengesellschaft and Aventis Pharma Deutschland GmbH. These positions have allowed him to apply his innovative ideas within established pharmaceutical frameworks, significantly contributing to the development of antibiotics and other medicinal compounds.

Collaborations: Joachim Wink has collaborated with notable professionals in his field, including Gerhard Seibert and Susanne Grabley. These partnerships have facilitated the exchange of ideas and advancements, fostering a collaborative environment that enhances the innovation process within biotechnological research and development.

Conclusion: Joachim Wink's contributions to innovation, particularly in antibiotic biosynthesis and pharmaceutical compounds, highlight the critical role of inventors in the healthcare sector. With 31 patents to his name and ongoing collaborations, Wink continues to make strides in addressing bacterial infections through biotechnology. His work exemplifies the impact of creativity and research in driving progress within the medical field.

Profile summary based on public USPTO records.